Newsletter | May 12, 2026

05.12.26 -- FDA's First cGMP Enforcement Action On AI Misuse In Drug Manufacturing

FOCUS ON OUTSOURCING

FDA's First cGMP Enforcement Action On AI Misuse In Drug Manufacturing

The warning letter, issued to Purolea Cosmetics Lab, describes a manufacturer that used AI agents to generate drug product specifications and more. Here's why the outsourced pharma industry should take note.

Collaborative Variability Reduction In Cell Culture Media

Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.

Keys To Achieving Unparalleled Flexibility In CHO Based Bioproduction

The dynamic growth and pace of change observed in novel mAb formats and cell and gene therapies emphasizes that biomanufacturing innovation is essential to deliver scale, speed, and sustainability.

The Challenges Of Moving A Bioconjugate From Clinic To Market

Working with a partner that provides a one-stop shop for bioconjugate development and manufacturing helps prevent missteps that threaten the delivery of life-saving drugs to patients who need them.

3 Keys To Rare Disease Clinical, Commercial Drug Product Manufacturing

The complex biology of rare diseases creates unique hurdles, making it difficult to design and implement a drug development program. Explore the unique considerations for drug product manufacturing.

Beyond The Booth: Shaping The Future Of Pharma Partnerships

Navigating the evolving pharmaceutical landscape requires a focus on regional supply chain resilience, integrated partnership models, and practical AI adoption. Understanding these key trends is essential.

Safely Scaling High Potency API Manufacturing

Scaling HPAPI production demands disciplined containment and exposure control. Integrated operating models help manage risk while enabling compliant, reliable scale‑up.

What's The Real Challenge In Biologic Manufacturing Scale-up?

As you plan your next stage of scale-up, take a moment to evaluate whether your manufacturing strategy is built around capacity — or around evolving market demand.

Solving Atypical Protein Expression With Transposases

To optimize productivity and avoid costly delays for complex proteins, researchers should leverage flexible platforms and experienced CDMOs in cell line development.

How To Choose The Right CDMO Partner For Fill And Finish

CDMO selection requires evaluating experience, quality standards, and flexibility. Assess technical transfer skills, supply chain security, and collaborative approach for a reliable, long-term project fit.

Application Of Plant And Process Models

Gain insight into innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing.

Integrated Services For Cell Line Preparation And Storage

Discover a comprehensive suite of services for the manufacture, characterization, and storage of cell banks as well as the advantages of working with an experienced partner.

OUTSOURCING SOLUTIONS

Capabilities Update March 2026: Fill/Finish - Novartis Contract Manufacturing

A Trusted New Partnership - August Bioservices

A Next-Generation Glass Prefillable Syringe - BD Medical - Pharmaceutical Systems

European Center Of Excellence For Clinical Biologics - Catalent

From Concept To Market: Mammalian Protein Development And Manufacturing - Avid Bioservices

Phase-Appropriate Solutions That Streamline Development - KBI Biopharma

mRNA/LNP Development And Manufacturing Services - Lonza

Connect With Bioprocess Online: